SGLT2 inhibitors and GLP-1 receptor agonists lower cardiovascular risk in type 2 diabetes, but a recent review suggests that ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

SGLT2 inhibitor use may help stabilize eGFR levels for patients with autosomal dominant polycystic kidney disease and type 2 diabetes, according to study data.“Given its unique pathophysiology, ...

SGLT2 inhibitors are medications designed to help manage blood sugar in people living with type 2 diabetes. Learn more about the different types, as well as the benefits and side effects.

Despite incomplete evidence, longevity enthusiasts are experimenting with SGLT2 inhibitors in their quest to live healthier ...

After the SGLT2 inhibitors were shown to benefit patients with type 2 diabetes, reducing cardiovascular events, including hospitalization for heart failure, the next natural research question ...

Israel: A new study published in JAMA Network Open highlights a key safety insight for patients with type 2 diabetes taking ...

SGLT2 inhibitors did not reduce the risk for adverse liver outcomes more than DPP-4 inhibitors in patients with type 2 diabetes and metabolic dysfunction–associated steatotic liver disease.

SGLT2 inhibitors have diuretic and anti-inflammatory effects that may contribute to improved outcomes in patients with PAH, particularly for those who have left-sided heart disease or other ...

A study found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to use these drugs in ...